Same day, different holiday: Mid-autumn festivals across East Asia
N.Korea could use nuclear weapons at any stage of conflict: Pentagon
Yoon hosts luncheon meeting with Korean atomic bomb victims in Hiroshima on Chuseok
Memorials commemorating Itaewon crowd crush to be erected at accident site
Swimmer, gamers celebrate Chuseok with gold medals
Opposition leader proposes meeting with Yoon amid growing party feud
The many regional flavors of songpyeon, a Korean holiday dessert
NewJeans hits 1 bln streams mark on Spotify with debut album
Expressway traffic congestion persists on 2nd day of extended Chuseok holiday
Whisky imports surge 40% through August, suggesting record-breaking year
Bridge Biotherapeutics regains lung disease pipelineBy Lim Jeong-yeo
Published : Nov. 10, 2020 - 17:58
Bridge Biotherapeutics will regain full global rights to the pipeline. It does not have to return the 45 million euro ($53.22 million) down payment.
BI’s decision to terminate the research was based on evidence of toxicity, Bridge Biotherapeutics explained in a regulatory filing, adding that the company will receive data compiled by BI reflecting 16 months of research.
Bridge Biotherapeutics will take the data to the US Food and Drug Administration in the first quarter of 2021 before taking the next step with the pipeline.
“Our confidence in the BBT-877 has not waned one bit,” a Bridge Biotherapeutics official told The Korea Herald.
Bridge Biotherapeutics’ license-out deal to BI, worth up to $1.27 billion, including royalties, catapulted the small Korean biotech, which operates based on a “no-research, development-only” model, into the public eye.
As an NRDO, Bridge Biotherapeutics’ role is to spot promising molecules early and pass them on to bigger pharmas with the money and resources to develop the pipelines further.
The gigantic deal with BI was a significant factor behind the company’s successful initial public offering in December 2019.
Meanwhile, obstacles and road bumps are regular occurrences in novel drug pursuits, as precedents have shown.
In a notable example, Hanmi Pharmaceutical’s pipeline HM12525A, after being returned by Janssen, was once again licensed out to American firm MSD in 2020 as a candidate treatment for nonalcoholic fatty liver disease.
By Lim Jeong-yeo (firstname.lastname@example.org)
S. Korea wins bronze in pistol mixed team event for 14th shooting medal
Traffic heavy on expressways following Chuseok
S. Korea to extend $5 mil worth of fertilizer aid to Ukraine via U.S. agency